AACR-NCI-EORTC 2025
Oct 22 - 26, 2025 | Boston, MA
The agents listed below are currently under investigation. Their safety and efficacy have not been established.
Poster
Vepdegestrant, a PROTAC ER Degrader, Induces Greater ER Degradation and Antitumor Activity Relative to SERDs in Preclinical ER+ Breast Cancer ModelsM Dorso et al